Drugs used to treat obesity may also influence the brain, and a review published in Science sets out how a clearer understanding of those effects could lead to treatments aimed at protecting memory and other cognitive abilities. Researchers at the University of Gothenburg and the University of Copenhagen wrote the review at the invitation of the journal, after assessing the existing evidence.
Semaglutide and tirzepatide are already prescribed for obesity and type 2 diabetes, and they act on biological processes that matter for brain function. Animal studies suggest GLP-1 drugs can affect memory and learning, but the findings in humans have been inconsistent. Patient record studies have linked GLP-1 treatment to a lower risk of dementia among people with type 2 diabetes. Those studies cannot show whether the drugs themselves explain the difference.
The evidence from clinical trials is less encouraging so far. In Novo Nordisk's EVOKE and EVOKE+ trials, semaglutide did not slow disease progression in people with early Alzheimer's disease, even though several biological markers of the disease changed. The review's authors note that this does not rule out benefits for other patients. People with obesity or type 2 diabetes often have trouble with attention, planning and processing speed, problems that are tied to metabolic and vascular health and might respond better to treatment.
The researchers say the central questions are whether these drugs can help people with obesity or diabetes keep their cognitive abilities, particularly if treatment starts before problems take hold, and which patients would benefit most. Christoffer Clemmensen, the senior author and a research group leader at the University of Copenhagen, said the team wants to separate the drugs' indirect effects, which work through metabolism, from any direct effects on the brain.
The authors call for clinical trials that track memory and other cognitive abilities from the start of treatment. They also stress the need to watch older and frail patients, for whom rapid weight loss and muscle loss could impair physical function and reduce any cognitive benefit.